Elevated risk of venous thromboembolic events in patients with inflammatory myopathies

Abstract

Venous thromboembolism (VTE) is a multifactorial disease manifesting as either deep vein thrombosis or pulmonary embolism. Its prevalence makes VTE a significant issue for both the individual – as a negative factor influencing the quality of life and prognosis – and the society due to economic burden. VTE is the third most common vascular disorder in Western countries, after myocardial infarction and stroke, making it a major cause of in-hospital mortality, responsible for 5%–10% of hospital deaths. Despite many studies conducted, only 50%–60% provoking factors have been identified, while the remaining 40%–50% have been classified as idiopathic or unprovoked. Chronic inflammatory disorders, with their underlying prothrombotic state, reveal an increased risk of VTE (six to eight times) compared with the general population. Among the inflammatory disorders, we can identify inflammatory myopathies – a group of rare, chronic diseases featuring weakness and inflammation of muscles with periods of exacerbation and remission; their main classes are polymyositis and dermatomyositis. The objective of this review is to emphasize the need of VTE prophylaxis in individuals with inflammatory myopathies in order to reduce morbidity and mortality rates among those patients and improve their quality of life and prognosis.

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

“…Inflammation is a risk factor for venous thromboembolism (VTE)-including deep vein thrombosis (DVT) and pulmonary embolism (PE)-and arterial thromboembolism (ATE). [7][8][9] Several attributes (including inflammatory diseases), family history, older age, Black race, smoking, hypertension, diabetes, cancer, hormone therapy, major surgical procedures, obesity and immobilisation are risk factors for VTE. 7 9-17 Increased incidence of VTE and ATE relative to the general population has been reported in patients with immune-mediated inflammatory diseases, including RA, [18][19][20][21][22][23][24][25][26][27][28][29][30] PsO 22 24 25 31-37 and PsA.…”

Quality Appraisal of Guidelines on Cancer-Associated Thrombosis Using AGREE II Instrument and Analysis of Current Status of New Oral Anticoagulants

“…Venous thromboembolism (VTE) is the third cause of mortality in cardiovascular disease in Western countries, accounting for 5% to 10% of the deaths of hospitalized patients after ischemic heart disease and stroke. 1 The relationship between cancer and VTE has been established. As early as 1823, Jean-Baptiste Bouillaud, a French physician, firstly described the association between cancer and thrombosis.…”

Deep venous thrombosis in an individual with statin-exposed anti-SRP myopathy: case report and review of literature

“…According to Virchow’s triad, three main plausible existing mechanisms including venous stasis, increased coagulability of blood and vessel wall damage contribute to the high risk of DVT [ 12 ], which is also applied to patients with anti-SRP myopathy. First of all, the patients with anti-SRP myopathy suffer from serious muscle weakness which may lead to venous stasis due to decreased mobility [ 13 ]. Moreover, inflammation is able to modulate thrombotic responses by upregulating procoagulants and damaging vessel wall.…”